Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5496866 | 0.99 | BRAF (0.48) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5491281 | 0.92 | SMN1; SMN2 (0.52) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5496861 | 0.89 | BRAF (0.48) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL27509542 | 0.85 | SMN1; SMN2 (0.58) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL27533283 | 0.84 | BRAF (0.61) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5495384 | 0.82 | RAB9A (0.56) | MEN1KMT2ASMN1; SMN2HTTMAPK1 | |
| SCHEMBL5493301 | 0.81 | RAB9A (0.55) | MEN1KMT2ASMN1; SMN2HTTMAPK1 | |
| SCHEMBL5496806 | 0.80 | HPSE (0.54) | MEN1KMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL6181468 | 0.80 | SMN1; SMN2 (0.50) | BRAFMEN1KMT2ASMN1; SMN2HTT | |
| SCHEMBL5491211 | 0.79 | HPSE (0.53) | MEN1KMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7297696-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2007-11-20 | — | — | US | claimed |
| CN-1259315-C | Antagonists of MCP-1 function and methods of use thereof | TELIK INC (US) | 2006-06-14 | — | — | CN | claimed |
| EP-1363897-B1 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK INC (US) | 2005-12-21 | — | — | EP | claimed |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | LABORDE EDGARDO (US) | 2005-03-10 | — | — | US | claimed |
| CN-1494539-A | Antagonists of MCP-1 function and methods of use thereof | ̩ | 2004-05-05 | — | — | CN | claimed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | claimed |
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-06-05 | — | — | US | claimed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105085-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | BRAF 1333/4885MEN1 2382/4885KMT2A 4655/4885 |
| US-20050054668-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | BRAF 1597/4885MEN1 2483/4885KMT2A 4673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.